New targeted pill takes on Hard-to-Treat pancreatic cancer

NCT ID NCT07303465

Recruiting now Disease control Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under control and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RNK08954 (an oral drug targeting the KRAS G12D mutation)
What this could lead to: If successful, this could lead to a new targeted treatment option for people with a specific genetic form of pancreatic cancer that is hard to treat.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to slow the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12D MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS G12D MUTATIONS PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

Nanjing Tianyinshan Hospital
RECRUITING

Nanjing, China
Shanghai GoBroad Cancer Hospital China Pharmaccutical University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.